Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves-Reference-Cited by-同舟云学术

Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves

Published:2007-11-01 Issue:11 Volume:85 Page:833-842
ISSN:0042-9686
Container-title:Bulletin of the World Health Organization
language:
Short-container-title:Bull. World Health Organ.

Author:

Kim Sun-Young¹,Salomon Joshua A²,Goldie Sue J¹

Affiliation:

1. Program in Health Decision Science, Health Policy and Management Department, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA.

2. Population and International Health Department, Harvard School of Public Health, Boston, MA, USA.

Publisher

WHO Press

Subject

Public Health, Environmental and Occupational Health

Reference39 articles.

1. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).;Beutels;Health Econ,2001

2. Global control of hepatitis B virus infection.;Kao;Lancet Infect Dis,2002

3. New tendencies and strategies in international immunization: GAVI and The Vaccine Fund.;Martin;Vaccine,2003

4. Impact of model, mathodological, and parameter uncertainty in the economic analysis of vaccination programmes.;Brisson;Med Decis Making,2006

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sustainable Development Goal Halftime Project: Benefit-Cost Analysis Using Methods from the Decade of Vaccine Economics Model;Journal of Benefit-Cost Analysis;2023-09-14

2. Buying vaccines through a single payment as a proxy for procuring vaccines via formularies;2022-08-10

3. Cancer control funding in Nigeria: A case for universal health coverage;Journal of Cancer Policy;2022-06

4. Applying the health capability profile to empirically study chronic hepatitis B in rural Senegal: a social justice mixed-methods study protocol;BMJ Open;2022-04

5. Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines;Vaccine;2021-11